Qhen do phase 3 triles start for cybn

The Phase 3 trial for CYB003, a deuterated psilocybin analog being developed by Cybin Inc., is expected to commence mid-2024. This trial will focus on the safety and efficacy of the drug in Major Depressive Disorder (MDD) and is a significant milestone in the development of CYB003. The Phase 3 trial follows the successful completion of the Phase 2 study, which showed promising results with 75% of patients achieving remission from depression symptoms at four months after dosing. The trial is eagerly anticipated as it has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA), which is expected to expedite the drug development timeline.